MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
5.54
+0.20 (3.75%)
At close: Sep 5, 2025, 4:00 PM
5.60
+0.06 (1.08%)
After-hours: Sep 5, 2025, 7:59 PM EDT
MannKind Revenue
MannKind had revenue of $76.53M in the quarter ending June 30, 2025, with 5.72% growth. This brings the company's revenue in the last twelve months to $301.74M, up 21.48% year-over-year. In the year 2024, MannKind had annual revenue of $285.50M with 43.50% growth.
Revenue (ttm)
$301.74M
Revenue Growth
+21.48%
P/S Ratio
5.34
Revenue / Employee
$741,366
Employees
407
Market Cap
1.70B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MNKD News
- 11 days ago - MannKind to Present at Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - GlobeNewsWire
- 12 days ago - SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH - Business Wire
- 13 days ago - MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal - Benzinga
- 13 days ago - MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript - Seeking Alpha
- 4 weeks ago - MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript - Seeking Alpha
- 4 weeks ago - MannKind Corporation: A Post-Q2 Assessment - Seeking Alpha
- 4 weeks ago - MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement - GlobeNewsWire